Compare ARK Genomic Revolution ETF (ARKG) vs Baxter International Inc (BAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Baxter International Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Baxter International Inc trades at $22.08 (market cap $11.68B). The key difference: Baxter International Inc pays a 0.88% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $29.22 |
52-Week Low | $23.09 | $15.80 |
Market Cap | — | $11.68B |
Enterprise Value | — | $19.35B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Baxter International (BAX) trades at $22.62, up 0.71% on the day, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains challenged with negative net income margins. Recent news highlights sustainability initiatives and upcoming Q2 2026 earnings, with analyst sentiment mixed but leaning hold.
Outlook hinges on operational turnaround amid margin pressures; upside exists if cost controls and innovation boost profits, but high debt and inconsistent cash flow pose risks. The stock offers speculative value for patient investors betting on recovery, but near-term volatility is likely until earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
